- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced May 22, 2026, 4:09 AM EDT